Balstilimab Monotherapy, Combination Shows Promise in Recurrent/Metastatic Cervical Cancer

Article

Balstilimab as a single agent and combined with zalifrelimab demonstrated promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent or metastatic cervical cancer.

Findings of 2 independent phase 2 trials presented during the 2020 ESMO Virtual Congress indicated that the investigative PD-1 inhibitor balstilimab (AGEN2034) as a single agent and combined with the CTLA-4 inhibitor zalifrelimab (AGEN1884) demonstrated promising objective response rates (ORRs), regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent or metastatic cervical cancer.1

In the modified intent-to-treat (ITT) population, single-agent balstilimab brought about a 14% ORR, which included 3 complete responses (CRs) and 20 partial responses (PRs); when explored in combination with zalifrelimab, the ORR increased to 22%, with 8 CRs and 23 PRs. Additionally, the median duration of response (DOR) was 15.4 months (1.1+ to 15.4) with balstilimab monotherapy and was not reached (1.3+ to 16.6+) when used in combination.

“This is, by far, the largest reported study of checkpoint inhibitors in [patients with] recurrent/metastatic cervical cancer reported to date. We demonstrated responses in both PD-L1–positive and PD-L1–negative tumors in patients treated with single-agent balstilimab and with the combination of balstilimab/zalifrelimab,” lead investigator David O’Malley, MD, professor of obstetrics and gynecology at The Ohio State University College of Medicine, said in a virtual presentation during the meeting. “These results demonstrate that both single-agent balstilimab and the balstilimab/zalifrelimab combination are effective and well tolerated in the second-line treatment of [patients with] recurrent/metastatic cervical cancer.”

The presentation follows a September 2020 announcement from the manufacturer of balstilimab, Agenus Inc., which stated that a rolling submission of a biologics license application to the FDA has been initiated for single-agent balstilimab for the treatment of patients with recurrent/metastatic cervical cancer.2

One of the phase 2 trials, both of which were parallel, single-arm studies, evaluated single-agent balstilimab at 3 mg/kg every 2 weeks (NCT03104699), while the second explored the PD-1 inhibitor at the same dosage in combination with zalifrelimab at a dose of 1 mg/kg every 6 weeks (NCT03495882), both in patients with recurrent/metastatic cervical cancer. Imaging was conducted every 6 weeks for 2 years.

To be eligible for enrollment, patients must have had histologically confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix that had relapsed following platinum-based therapy, measurable baseline disease, and an ECOG performance status of 0 or 1.

The primary end point of the trial was ORR via RECIST v1.1 criteria, as assessed by an independent review committee; secondary end points were progression-free survival, overall survival, DOR, and safety. PD-L1 positivity was defined as a combined positive score (CPS) of 1% or higher.

In the single-agent trial, 161 patients comprised the safety population, and 160 were in the modified ITT population; 138 patients had received 1 or more prior line of chemotherapy. The median age was 53 years, and 47% of patients had an ECOG performance status of 0. A total 62% of patients had a CPS of 1% or higher, 63% had squamous cell histology, and 37% had adenocarcinoma/adenosquamous histology.

In the combination trial, 155 patients were in the safety population, and 119 had received 1 or more lines of chemotherapy. A total 143 patients comprising the modified ITT population with baseline measurable disease. The median age was 50 years, and 57% of patients had an ECOG performance status of 0. Fifty-five percent of patients had a CPS of 1% or higher, and 70% had squamous histology. Thirty percent of patients had adenocarcinoma/adenosquamous histology.

In patients who received 1 or more lines of prior chemotherapy, the ORR in the single-agent balstilimab trial was 13%, with 3 CRs and 15 PRs. For those who received the combination and prior chemotherapy, the ORR was 20%, with 6 CRs and 18 PRs.

When stratified by histology, the ORR was higher in patients with squamous cell carcinoma who received the combination (27%) versus the single agent (18%), suggesting a predictor of response, O’Malley explained. For the adenocarcinoma/adenosquamous/other histology, the ORRs were 8% for those on single-agent balstilimab and 5% for patients on the combination.

Moreover, on the monotherapy study, the ORRs were 19%, 10%, and 0% for those with PD-L1–positive disease, PD-L1–negative disease, and unknown PD-L1 status, respectively. In the combination study, these rates were 27%, 11%, and 21%, respectively.

Regarding safety, the treatment was found to be well tolerated in both studies and no new safety signals were identified, with all-grade endocrine disorders more common with the combination compared with single-agent balstilimab (20.6% vs 9.3%, respectively).

The combination trial also saw more immune-related adverse effects (irAEs) than the single-agent study, O’Malley noted. Specifically, gastrointestinal (GI) disorders occurred in 8.4% and 5.6% of the combination and monotherapy arms, respectively, as well as laboratory abnormalities (11.6% vs 5.6%) and endocrine disorders (18.7% vs 5.0%). Grade 3 or higher immune-related treatment-related adverse effects were GI disorders (2.6% with the combination vs 3.1% with balstilimab alone), laboratory abnormalities (3.9% vs 1.2%, respectively), and skin and subcutaneous tissue disorders (1.9% vs 0.6%).

“Given the limited treatments available for our patients with recurrent/metastatic cervical cancer, both single-agent balstilimab and the combination of balstilimab/zalifrelimab present important treatment options for our patients,” O’Malley concluded.

References:

1. O’Malley DM, Oaknin A, Monk B, et al. Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials. Presented at: 2020 ESMO Congress; September 19-21, 2020; virtual. Abstract LBA34.

2. Agenus initiates rolling BLA submission of balstilimab for recurrent/metastatic cervical cancer. News release. Agenus Inc. September 18, 2020. Accessed September 18, 2020. https://bit.ly/35OGfVH.

Related Videos
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.
Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.
Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.
Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.
Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.
The 12-month progression-free survival rates among patients with high-risk locally advanced cervical cancer were comparable with durvalumab plus chemoradiotherapy vs placebo plus radiotherapy.
PARP inhibitors like rucaparib should be considered to treat all kinds of patients, including those who have deleterious mutations and HIV, according to Amit Oza, MD, MBBS, FRCPC.
PARP inhibitors such as rucaparib appear to garner the most benefit in the early maintenance setting in patients with ovarian cancer who have less advanced disease and less heterogeneity, according to Amit Oza, MD, MBBS, FRCPC.
Abiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.
Related Content